Valuation: Insmed Incorporated

Market Cap 26.21B 23.51B 21.67B 19.68B 37.24B 2,458B 38.28B 259B 103B 1,317B 98.38B 96.29B 4,163B P/E 2026 *
-72.9x
P/E 2027 * 161x
Enterprise Value 25.7B 23.05B 21.24B 19.29B 36.51B 2,410B 37.53B 254B 101B 1,291B 96.45B 94.4B 4,081B EV / Sales 2026 *
13.8x
EV / Sales 2027 * 8.44x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+2.92%
1 week+14.41%
Current month+6.14%
1 month+18.78%
3 months-11.32%
6 months+17.90%
Current year-31.34%
1 week 106.16
Extreme 106.16
119.85
1 month 92.62
Extreme 92.625
119.85
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.31
Extreme 11.31
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Chief Tech/Sci/R&D Officer 62 19/12/2019
Chief Operating Officer 57 14/11/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
19/10/26 Free

Director

6,139 0.0028%
19/10/26 Free

Director

6,139 0.0028%
9/9/26 Sell

Director

-25,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
+2.92%+14.41%-37.74%+403.12% 26.21B
+0.01%+11.10%+60.83%+70.43% 68.32B
+1.22%+9.56%+15.97%+90.23% 60.26B
+0.24%+1.35%+23.78%+97.55% 55.86B
+1.60%+19.44%+28.80%+112.95% 48.43B
-1.32%+4.78%+29.15%+40.40% 45.34B
-3.54%-0.60%+207.76%+879.50% 41.76B
-3.33%+6.90%+22.78%+48.07% 34.5B
-2.19%-3.71%+90.94%+66.33% 33.8B
-1.77%+0.83%+46.57%-0.16% 25.96B
Average -0.62%+6.30%+48.88%+180.84% 44B
Weighted average by Cap. -0.46%+5.80%+49.76%+168.44%

Financials

2026 *2027 *
Net sales 1.86B 1.67B 1.54B 1.4B 2.64B 175B 2.72B 18.42B 7.34B 93.5B 6.99B 6.84B 296B 2.99B 2.68B 2.47B 2.25B 4.25B 281B 4.37B 29.61B 11.8B 150B 11.23B 10.99B 475B
Net income -357M -320M -295M -268M -508M -33.5B -522M -3.54B -1.41B -17.95B -1.34B -1.31B -56.75B 167M 150M 138M 126M 238M 15.7B 244M 1.66B 660M 8.41B 628M 615M 26.59B
Net Debt -514M -461M -425M -386M -731M -48.24B -751M -5.09B -2.03B -25.84B -1.93B -1.89B -81.7B -949M -851M -784M -712M -1.35B -88.98B -1.39B -9.39B -3.74B -47.67B -3.56B -3.49B -151B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
10/11/26 US$119.49 +2.92% 3,346,741
09/11/26 US$116.10 +1.48% 2,668,854
06/11/26 US$114.41 +5.19% 3,379,993
05/11/26 US$108.76 -1.13% 2,616,308
04/11/26 US$110.00 +5.32% 4,944,543
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
119.49USD
Average target price
194.18USD
Spread / Average Target
+62.51%
  1. Stock Market
  2. Stocks
  3. INSM Stock